Systemic Inflammation Score as a Novel Prognostic Indicator for Patients Undergoing Video-Assisted Thoracoscopic Surgery Lobectomy for Non-Small-Cell Lung Cancer

Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score‐matching study

“…Second, as the mainstay of human immune responses, lymphocytes can assist to enhance cancer immune‐surveillance and inhibit tumour growth by secreting a series of cytokines that participate in the cellular immunity. A sharp decline of peripheral lymphocyte counts can lead to a weak and insufficient immune response to oncological progression . Finally, most recent evidence demonstrates that monocytes can be recruited in carcinomatous tissues and further differentiate into tumour‐associated macrophages, which play a key role in the tumour microenvironment, cancer cell proliferation and encouraging metastasis .…”

“…Respiratory comorbidity was defined as the presence of one or more respiratory diseases, including chronic obstructive pulmonary disease, emphysema, lung bullae, asthma, tuberculosis, pneumonia, bronchiectasis, lung abscess and interstitial lung diseases. Cardio‐cerebrovascular comorbidity included hypertension, coronary heart diseases, peripheral arterial diseases, stroke, aortic aneurysm and chronic heart failure …”

“…OS was defined as the survival time from the operation day to the date of death from any cause or to the time of censoring at the last follow‐up date. DFS was defined as the survival time from the operation day to the detection of cancer recurrence or metastasis …”

“…Current evidence recognizes that systemic inflammatory response, which is featured by changes in peripheral biomarkers and alterations in levels of inflammation‐linked proteins, frequently accompany with numerous cancer patients and further promote carcinomatous pathogenesis and progression . Systemic inflammation indicated by a range of circulating biochemical markers, such as the elevated neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and lymphocyte‐to‐monocyte ratio (LMR) and the decreased serum albumin (sAlb) and haemoglobin levels, has been reported to predict unfavourable cancer prognosis . These biomarkers can provide readily available and objective information to help oncologists to estimate patient outcomes since they are easily obtained with low healthcare costs in routine clinical practice …”

“…Systemic inflammation indicated by a range of circulating biochemical markers, such as the elevated neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and lymphocyte‐to‐monocyte ratio (LMR) and the decreased serum albumin (sAlb) and haemoglobin levels, has been reported to predict unfavourable cancer prognosis . These biomarkers can provide readily available and objective information to help oncologists to estimate patient outcomes since they are easily obtained with low healthcare costs in routine clinical practice …”